Z
20.09
1.47 (7.89%)
| Previous Close | 18.62 |
| Open | 18.74 |
| Volume | 105,939 |
| Avg. Volume (3M) | 199,646 |
| Market Cap | 845,996,160 |
| Price / Sales | 56.90 |
| Price / Book | 3.56 |
| 52 Weeks Range | |
| Earnings Date | 11 Nov 2025 |
| Operating Margin (TTM) | -373.30% |
| Diluted EPS (TTM) | -3.89 |
| Total Debt/Equity (MRQ) | 0.43% |
| Current Ratio (MRQ) | 6.47 |
| Operating Cash Flow (TTM) | -137.62 M |
| Levered Free Cash Flow (TTM) | -77.73 M |
| Return on Assets (TTM) | -56.70% |
| Return on Equity (TTM) | -115.47% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Zenas BioPharma, Inc. | Bearish | - |
AIStockmoo Score
-0.8
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | -1.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.5 |
| Average | -0.75 |
|
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 21.20% |
| % Held by Institutions | 74.88% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |